MedTrace Logo

Homocysteic Acid Biostimulator for Photoaged Facial Skin

NCT07722351 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-07-23

No results posted yet for this study

Summary

This study evaluated whether a chemical skin biostimulator containing ammonium trichloroacetate, homocysteic acid, phytic acid and citric acid can improve signs of photoaged skin in women with mature skin. Twenty-five women received four treatment sessions two weeks apart, followed by a home-care skincare regimen. Skin firmness, wrinkles, skin texture, hydration, sebum production and, in participants with hyperpigmentation, skin tone uniformity were measured before treatment and at 2 and 12 weeks after the treatment series to determine whether the biostimulator produces lasting improvement in photoaged skin without the downtime associated with traditional chemical peels.

Conditions

  • Skin Aging
  • Hyperpigmentation

Interventions

PROCEDURE

Chemical skin biostimulation with ammonium trichloroacetate and homocysteic acid

A four-session chemical skin biostimulation procedure using a topical formulation containing ammonium trichloroacetate (ATCA), homocysteic acid (HoA), phytic acid and citric acid (PRX plus, WiQO, Trieste, Italy). At each session, three product layers were applied to predefined facial areas (forehead, nose, cheeks, chin, upper lip) with massage until absorption, followed by cold-water rinse. Sessions were repeated at 14-day intervals. Participants additionally followed a standardised home-care regimen: a regenerating shea-butter cream each morning, a glycolic-acid-containing fluid each evening, and, for participants with hyperpigmentation, a lightening serum applied twice daily to affected areas, together with daily broad-spectrum sunscreen (SPF 50+).

Sponsors & Collaborators

  • WiQO (Trieste, Italy)

    collaborator UNKNOWN

  • Medical University of Silesia

    lead OTHER

Principal Investigators

  • Anna Deda, PhD · Medical University of Silesia in Katowice

  • Dominika Wcisło-Dziadecka, Prof · Medical University of Silesia in Katowice

  • Sławomir Wilczyński, Prof · Medical University of Silesia in Katowice

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
39 Years
Max Age
69 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-29
Primary Completion
2026-04-01
Completion
2026-04-01

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07722351 on ClinicalTrials.gov